Development and implementation of the Ebola Exposure Window Calculator: A tool for Ebola virus disease outbreak field investigations.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 26 03 2021
accepted: 20 07 2021
entrez: 5 8 2021
pubmed: 6 8 2021
medline: 30 11 2021
Statut: epublish

Résumé

During an Ebola virus disease (EVD) outbreak, calculating the exposure window of a confirmed case can assist field investigators in identifying the source of infection and establishing chains of transmission. However, field investigators often have difficulty calculating this window. We developed a bilingual (English/French), smartphone-based field application to assist field investigators in determining the exposure window of an EVD case. The calculator only requires the reported date of symptoms onset and the type of symptoms present at onset or the date of death. Prior to the release of this application, there was no similar electronic capability to enable consistent calculation of EVD exposure windows for field investigators. The Democratic Republic of the Congo Ministry of Health endorsed the application and incorporated it into trainings for field staff. Available for Apple and Android devices, the calculator continues to be downloaded even as the eastern DRC outbreak resolved. We rapidly developed and implemented a smartphone application to estimate the exposure window for EVD cases in an outbreak setting.

Identifiants

pubmed: 34352008
doi: 10.1371/journal.pone.0255631
pii: PONE-D-21-09987
pmc: PMC8341611
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0255631

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Afr Health Sci. 2017 Mar;17(1):225-236
pubmed: 29026397
Clin Infect Dis. 2015 Apr 1;60(7):1079-82
pubmed: 25516185
Science. 2014 Nov 21;346(6212):991-5
pubmed: 25414312
J Infect. 2017 Mar;74(3):294-301
pubmed: 27840270
Lancet Infect Dis. 2015 Mar;15(3):320-6
pubmed: 25619149
Lancet. 2019 Mar 2;393(10174):936-948
pubmed: 30777297
PLoS One. 2021 Feb 19;16(2):e0247002
pubmed: 33606709
Lancet. 2018 Jul 21;392(10143):213-221
pubmed: 30047375
Virus Evol. 2016 Jun 22;2(1):vew016
pubmed: 28694998
Clin Infect Dis. 2015 Oct 1;61(7):1135-40
pubmed: 26129757
N Engl J Med. 2015 Jan 1;372(1):40-7
pubmed: 25372658
N Engl J Med. 2014 Oct 16;371(16):1481-95
pubmed: 25244186

Auteurs

Amy Whitesell (A)

National Centers for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, United States of America.

Nirma D Bustamante (ND)

Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Miles Stewart (M)

Applied Physics Laboratory, Johns Hopkins University, Baltimore, Maryland, United States of America.

Jeff Freeman (J)

Applied Physics Laboratory, Johns Hopkins University, Baltimore, Maryland, United States of America.

Amber M Dismer (AM)

Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Walter Alarcon (W)

National Institute of Occupational Safety and Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Aaron Kofman (A)

National Centers for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Amen Ben Hamida (A)

Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Stuart T Nichol (ST)

National Centers for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Inger Damon (I)

National Centers for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Dana L Haberling (DL)

National Centers for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Mory Keita (M)

World Health Organization, Geneva, Switzerland.

Gisèle Mbuyi (G)

Ministry of Health, Kinshasa, Democratic Republic of Congo.

Gregory Armstrong (G)

National Centers for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Derek Juang (D)

Department of Medicine, University of California San Diego, San Diego, California, United States of America.

Jason Dana (J)

Applied Physics Laboratory, Johns Hopkins University, Baltimore, Maryland, United States of America.

Mary J Choi (MJ)

National Centers for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH